INTRODUCTION
Group B streptococcus (GBS) has long been recognized as a significant cause of neonatal and perinatal morbidity. Among pregnant women, infection commonly manifests as localized uterine infection and chorioamnionitis. In infants, GBS infection often presents as neonatal sepsis, pneumonia and meningitis. 1 The incidence of infection has been estimated at 0.8±5.5/1000 live births, an estimate that has remained virtually unchanged for the last three decades. Case-fatality rate is reported to range from 5% to 15%. 1 ± 6 Although survival has improved over the past years, GBS sepsis has been found to increase birth weight±specific mortality up to eight-fold in preterm infants and a little more than 40-fold in term infants. 4 The morbidity associated with GBS infection, and the attendant costs of caring for infected mothers and infants has stimulated investigation into the factors that increase the risk of disease, the pathogenesis of the disease itself and new therapeutic modalities that may be applied in its treatment. Treatment is best instituted during the intrapartum period, with resulting prevention of transmission of infection from the colonized mother to the infant. 1,7 ± 13 Two-thirds of early-onset GBS disease in the infant presents within 6 hours of birth, and 60±80% of cases present within the first 24 hours of life. 1, 7 Treatment after delivery, will, in most instances be too late to prevent transmission.
In 1992, both the AAP and the ACOG developed guidelines advocating the use of selective intrapartum antibiotic prophylaxis. 7, 11 The CDC has since published consensus guidelines that were developed with the participation of representatives from both organizations as well as experts from relevant disciplines. 13 A key to guidelines has been the identification of factors that are associated with an increased risk of early-onset GBS disease. These risk factors include: (1) preterm labor ( <37 weeks), (2) preterm, premature rupture of membranes, (3) prolonged rupture of membranes ( >18 hours), (4) maternal fever during labor, and (5) previous delivery of a sibling with invasive GBS disease. Multiple births, GBS bacteriuria during pregnancy, and birth weight less than 2500 g have also been cited by some as additional risk factors for infection. 6, 7, 11, 13 The ultimate test of the effectiveness of these guidelines is, of course, how they are applied in the practice setting and whether they affect the incidence and severity of GBS disease.
According to the AAP's initial guidelines (1992), selective intrapartum antibiotic prophylaxis was recommended for women identified as GBS carriers by prenatal screening as early as 28 weeks, if they had one or more of the risk factors that have been previously mentioned. (Multiple births were included in these guidelines as a risk factor.
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) The ACOG, however, advocated intrapartum antibiotic prophylaxis for all women with one or more risk factors. 7 In our study, we looked at the clinical course and outcomes of infants born to GBS-colonized women who delivered in our hospital over the 1-year period immediately following the publication of the initial AAP and ACOG guidelines. We reviewed the mothers' charts as well as those of their infants to see how these recommendations for selective intrapartum antibiotic
OBJECTIVE:
To evaluate how guidelines for the use of intrapartum antibiotics for the prevention of early -onset Group B streptococcal infection are utilized in a clinical setting.
STUDY DESIGN:
Review of maternal / infant records for the year 1993 in a perinatal center.
RESULTS:
Intrapartum antibiotics were administered to 77.8% of 443 Group B streptococcus ( GBS ) -colonized women. There were 452 infants born to these mothers, of which four developed GBS infection. During the same period, an additional 11 infants with GBS infection were born to women with``negative'' or``unknown'' GBS status ( the women did not receive intrapartum antibiotics ) . Infants of GBS -colonized women who had not receive antibiotics were more likely to develop infection than GBS negative or unknown status, odds ratio 9.0, 95% confidence intervalprophylaxis were carried out and how they affected neonatal outcomes. Early-onset neonatal GBS infection was defined by either a positive blood culture or a positive test for bacterial antigens in the presence of clinical signs of infection.
METHODS
GBS-colonized pregnant women who delivered at our hospital in the 1-year period from January 1 to December 31, 1993 were identified using computerized records. These were women who had a positive screen for GBS colonization during the prenatal period. Screening was performed by obtaining rectovaginal swabs and placing these in Stuart's transport medium. These swabs were then inoculated onto agar plates both directly and after incubation in selective broth medium for 6±8 hours. Screening was performed at approximately 26±28 weeks' gestation among women receiving prenatal care at clinics affiliated with our hospital. Intrapartum antibiotics were administered to women based on published AAP and ACOG guidelines (prolonged rupture of membranes, PROM >12 hours, urinary tract infection, fever, premature labor, multiple gestation, unknown, or GBS-colonized status).
Data Collection
Medical records were reviewed for maternal demographic data, pregnancy history (gravidity, parity, number of fetuses, number of prenatal visits, history of alcohol, cigarette or illicit drug use, infection with other organisms during the prenatal period), and intrapartum course (presence of chorioamnionitis, maternal fever, mode of delivery and use of intrapartum antibiotics, including the number of doses).
We reviewed the infant's birth information (gestational age, birth weight, fetal growth, Apgar scores, and cord pH when available), laboratory studies performed and their results (CBC, blood culture, urine, or CSF testing for bacterial antigens, chest radiography, and lumbar puncture), and the infant's course in the hospital. We looked, in particular, at the occurrence of GBSassociated complications such as sepsis or bacteremia, pneumonia, persistent pulmonary hypertension, meningitis, or localized GBS infection. In addition, we reviewed interventions required (ventilator or oxygen support, volume expansion, pressor support), antibiotic use, length of hospitalization, and condition at the time of discharge.
We then reviewed the hospital's computerized records for all infants who were born during the same year and who were diagnosed to have GBS infection. We were able to identify an additional group of infants who either had a blood culture that was positive for GBS or who had a positive test for GBS antigens in the urine or CSF. These infants had not been included in the original study group because their mothers were either GBS negative or had``unknown'' GBS status. After identifying these infants, we reviewed the medical records of the mother±infant dyads for information as we had done with the study population of colonized women.
Definitions are shown on Table 1 . The definition of chorioamnionitis used in this study was based on the clinical definition used by the obstetricians in our institution and may differ from that used in other studies.
Statistical Analysis
Significance testing was performed using Fischer's exact test. The odds ratio and 95% confidence interval was calculated to evaluate the relationship between clinical factors and outcome.
RESULTS
There were 7993 deliveries at our institution during the study year. Prenatal GBS test results were obtained in 2448 women. Of the women tested, 487 were identified to have GBS colonization before delivery. We were able to obtain the medical records of 443 (91%) of these women, as well as information on the outcomes of their infants.
Maternal Data
The GBS-colonized mothers had a mean age of 256 years. The study population consisted predominantly of African-American (77%), single (70%), unemployed (69%) women, most of whom were Medicaid recipients (66%). More than half had at least a high Table 2 .
Median gravidity and parity were 3 and 1, respectively. Nine of the mothers had a multiple gestation (twins). Only a small number (eight women) had no or limited prenatal care. About a third used cigarettes, alcohol, or illicit drugs or a combination thereof during their pregnancy. Fifty-seven (12.9%) of the women were found to have GBS urinary tract infection and a little more than half (53.3%) were found to have concomitant infection with other organisms during the prenatal period. These were treated as indicated.
When we examined the intrapartum data for some factors that are known to increase the risk for GBS infection in the infant, we found that 24 (5.4%) of the mothers had chorioamnionitis and 121 (27.4%) had PROM greater than 12 hours. Approximately threefourths (77.8%) of all women received antibiotics and this was evenly divided between those who received only one dose and those who received two or more doses of antibiotics. The C-section rate was 18.7% and there were 20 (4.5%) mothers who delivered by either forceps or vacuum-assisted vaginal delivery.
Infant Outcome
There was a total of 452 infants born to the 443 mothers included in the study. We were able to obtain information on gestation, birth weights, and sex distribution on all infants as well as information on the outcomes of 451 of these infants.
Mean gestational age was 38.72.7 weeks, with about 12% of infants born prematurely. Mean birth weight was 3181684 g, and 46% of infants were male.
Of the 451 infants on whom information was available, 345 were born to mothers who received intrapartum antibiotics. A total of four infants in the entire study group developed evidence of GBS infection (one culture proven, three antigenuria). Two of the four were born to mothers who received intrapartum antibiotics. There was no significant difference observed in the incidence of GBS sepsis among infants of mothers who received intrapartum antibiotics compared to infants of those who did not receive intrapartum antibiotic prophylaxis.
Only one of the infants born to colonized women was found to have culture-positive GBS sepsis. This was a 29 weeks' gestation male infant who was born as the second of twins to a mother who had PROM >18 hours and who had GBS UTI during the earlier prenatal period. This mother had been treated for the UTI and was found to be GBS negative on repeat testing. No intrapartum antibiotic was given to this mother. The pregnancy, in addition, was complicated by twinto-twin transfusion, with this infant weighing twice as much as the first twin, who was stillborn.
There were an additional three infants who had negative blood cultures but who had GBS bacterial antigens in their urine. The sole culture-positive infant was also found to have GBS bacterial antigens in his urine. All of these four infants were symptomatic for infection within 24 hours of delivery. One of them died. This was a 26 weeks' gestation male infant born first of twins to a mother who had GBS UTI during pregnancy and whose intrapartum course was complicated by PROM >18 hours and chorioamnionitis. This mother received one dose of ampicillin before delivery. The infant developed pneumonia and had GBS bacterial antigens in his urine.
Of the 451 infants born to GBS-colonized women, 11 (2.4%) developed pneumonia, 4 (0.9%) had persistent pulmonary hypertension, and none was found to have meningitis. Six infants (1.3%) died in the neonatal period and there were four stillbirths (0.9%).
Approximately half of the infants (53.9%) had no laboratory studies done. Two hundred four had a CBC drawn, of which 27 (13.2%) had an abnormal WBC count and 33 (16.2%) had an I:T neutrophil ratio greater than 0.2. Blood cultures were obtained on 168 infants, bacterial antigens tested in 57, and a spinal tap performed on 45 infants.
A majority (92%) of the infants received antibiotics. Most of these infants received four doses of ampicillin over a period of 2 days. A small percentage (3.1%) required ventilator support and a total of 35 (7.8%) infants required oxygen. Only a small number required volume expansion or pressor support. There were five infants who were transferred to another hospital, and of the remaining infants, 431 (96.6%) were discharged home with no requirement for oxygen, medications, or a home monitor. Median length of stay was 2 days.
Among all infants born during 1993, an additional 11 infants were diagnosed to have GBS infection in the neonatal period. Four infants had a positive blood culture. Eight infants (including one culture-positive infant) had a positive test for bacterial antigens. One of these infants was found to have antigens in both urine and spinal fluid specimens. Four infants were also found to have pneumonia and one was diagnosed to have meningitis. One infant had asymptomatic GBS antigenuria. None of these infants died and all had a good outcome, with none of them going home on oxygen, medications or a home monitor. (These 11 infants were born to women who were either GBS-negative or had``unknown'' GBS status. Five of the mothers of these 11 infants were GBS negative and six mothers had``unknown'' GBS status.) Six of the mothers were primigravidas and seven were primiparous. All of these women had more than one prenatal visit and none had any known history of drug, alcohol, or cigarette use. Seven women had chorioamnionitis or PROM greater than 12 hours. Only two of these mothers, both of whom were GBS negative, received intrapartum antibiotics. None of the six mothers with``unknown'' GBS status received intrapartum antibiotic prophylaxis.
The association between known risk factors and the occurrence of early-onset GBS sepsis was examined in the 11 infants born to women with GBS negative or unknown status and 451 born to GBS positive women. Chorioamnionitis, maternal fever, PROM, GBS UTI in the mother, prematurity, birth weight less than 2500 g, and twin pregnancy were all found to be significantly associated with an increased occurrence of proven or probable early-onset GBS sepsis in the infant (Table 3) . Race, maternal use of illicit drugs or alcohol and concomitant infection with other organisms during pregnancy did not alter the risk for neonatal GBS infection.
Infants whose mothers did not receive intrapartum antibiotics were nine times more likely to have either proven or probable GBS sepsis. Of the five infants whose blood cultures were positive, none of the mothers received intrapartum antibiotics. Eleven mothers of the 15 infants who had either a positive blood culture or positive test for bacterial antigens likewise did not receive any intrapartum antibiotics. There did not appear to be any difference in the incidence of sepsis between those who received only one versus two or more doses of antibiotics. There were 7937 live births in our institution during the study period. Incidence of early-onset neonatal GBS disease was 1.8/1000 live births. Case fatality rate was 7.1%.
DISCUSSION
The results of this study support the use of intrapartum antibiotics as a means of preventing invasive early-onset GBS disease. When infants born to mothers who were identified to be GBS colonized were evaluated, there was no significant difference in the incidence of early-onset neonatal GBS sepsis among those infants whose mothers received antibiotics compared to those whose mothers didn't receive intrapartum antibiotic prophylaxis. When the additional group of 11 infants and their mothers was included in the analysis, we found that infants of mothers who did not receive intrapartum antibiotics were more likely to develop GBS infection. During the study period, there were 15 infants born who were found to have either a positive blood culture or a positive test for GBS antigens. Only four of these infants' mothers received intrapartum antibiotics.
This raises the question of how effective prenatal screening is in identifying likely candidates for antibiotic prophylaxis. It is interesting to note that majority of the infants (11/15) with invasive GBS disease were not identified based on maternal prenatal screening either because their mothers were GBS negative on the screen or had`u nknown'' status. One possible reason for a GBS negative screen, apart from a false-negative test or errors in technique, would be the timing of the test. Past studies have shown, however, that cultures obtained in the late second to third trimester, as was done in this study, are reasonably predictive of cultures at the time of delivery. 9 The need remains for rapid and more effective means of identifying GBS-colonized pregnant women, preferably at or close to the time of delivery. In this regard, the use of Strep B optical immunoassay appears to be promising. 6, 14 The number of infected infants born to mothers with``unknown'' status highlights the importance of considering such mothers for intrapartum antibiotic prophylaxis in the presence of known risk factors for infection. Indeed, when we reviewed these infants' data to see if their mothers would have qualified for intrapartum antibiotic prophylaxis based on the CDC consensus guidelines that were published in 1996, 13 excluding GBS colonization as a risk factor, all but one of the six mothers with unknown status would have qualified for intrapartum antibiotics. Three pregnancies were at <37 weeks' gestation, three mothers developed fever, and two had PROM >18 hours (three had a combination of these factors). Review of the data shows that none of these mothers received intrapartum antibiotics.
In this study a large percentage (76.6%) of GBS-colonized women were treated with intrapartum antibiotics. This, despite the finding that only about 32.2% had at least one risk factor (GBS UTI during pregnancy, prematurity, PROM >12 hours, maternal fever) that qualified them for intrapartum prophylaxis based on the initial AAP guidelines. A large number of women received intrapartum prophylaxis despite the absence of risk factors, suggesting some degree of overtreatment. Such violations of protocol guidelines have been recognized in a previous study where protocol errors observed included failure to give indicated prophylaxis, and administration of prophylaxis when not indicated. 15 In our study we found similar errors. Twenty-six (18%) of 145 GBS-colonized women with at least one risk factor did not receive intrapartum antibiotics. Conversely, 74% of women with no risk factors received at least one dose of intrapartum antibiotics. This apparent bias in favor of treating a pregnant woman identified as a GBS carrier despite the absence of risk factors has also been noted in a previous study. 16 It may, in part, be due to the ever-present concern that most physicians have regarding the adverse outcomes associated with GBS infection. The new consensus guidelines, recommending treatment of all women identified as GBS carriers by screening done at 35±37 weeks 13 simplifies this portion of the decision-making process to some extent.
Intrapartum antibiotic prophylaxis is not without its risks, as has been recognized by a number of researchers. 7, 9, 10 Among the risks cited are drug allergy or anaphylaxis and the alteration of normal bacterial flora in favor of resistant organisms. Admittedly, the probability of an allergic reaction to penicillin or the occurrence of an anaphylactic reaction are relatively low, being estimated at 5/100 and 9.5/100,000, respectively. 10 As the use of intrapartum prophylaxis becomes more common, however, this raises the concern that there will be an increased occurrence of these adverse effects of antibiotic use. These adverse effects notwithstanding, it is generally recognized that some form of intrapartum antibiotic prophylaxis is beneficial, both in reducing the number of cases of early-onset neonatal GBS sepsis and in reducing the overall cost of treating GBS infection. 1, 10, 13, 17, 18 One of the difficulties that have been recognized in the use of selective intrapartum antibiotic prophylaxis is that it will inevitably fail to prevent a small but significant percentage of cases of earlyonset neonatal GBS disease. 1, 10, 13, 14, 17 Using the CDC consensus guidelines, it has been estimated that selective intrapartum prophylaxis based on prenatal cultures at 35±37 weeks would fail to prevent 14% of cases of early-onset GBS disease. 13 Benitz et al. 14 in a decision analysis of various strategies found an even higher figure, determining that about 25% of cases of early-onset GBS infection would not be prevented using CDC consensus guidelines. In our study, of the 14 infants with early-onset GBS sepsis, 13 were born to mothers with at least one risk factor (exclusive of GBS colonization). Only 1 (7%) of the 14 mothers did not qualify for intrapartum antibiotic prophylaxis based on risk factors.
The use of intrapartum antibiotic prophylaxis is, of course, no guarantee of a good outcome for the infant. The only infant who died of GBS sepsis in our study was born to a mother who received intrapartum antibiotics. This infant, admittedly, had several risk factors (prematurity, twin gestation, maternal GBS bacteriuria, chorioamnionitis, and PROM) that increased the likelihood of a poor outcome. What is notable is that all of the other infants with GBS sepsis had a fairly good outcome with none going home on oxygen, medications, or a home monitor. This may reflect continuing improvement in various aspects of neonatal care. None of the infants in our study who stayed beyond 7 days of age developed late-onset GBS sepsis. Ninety-two percent of the infants were treated with at least four doses of ampicillin. Majority of the infants (60%), however, were discharged by 2 days of age. Information on the effect of antibiotic use on risk of infection with resistant organisms at a later age was not available.
In summary, this study affirms the use of intrapartum antibiotics as a useful tool in the prevention of early-onset neonatal GBS infection. Guidelines that were developed by the AAP and the ACOG in the past, and more recently by the CDC 7,11 ± 13 help clinicians determine how to approach this important cause of maternal and neonatal morbidity. The need remains for a more effective screening tool than what is currently available. We do not yet have the final answer on the best way to treat and prevent GBS infection. Despite the use of prenatal screening for GBS and intrapartum antibiotic prophylaxis, there will be cases of early-onset neonatal GBS infection that occur because of errors in the screening procedure, failure to administer intrapartum prophylaxis when indicated and other factors that may be beyond the control of the physician and other caregivers. The use of intrapartum antibiotic prophylaxis also does not address how best to prevent late-onset GBS infection, a less frequent, but nonetheless, important cause of morbidity. Continued assessment of how guidelines are carried out in the clinical setting and how they affect maternal and neonatal outcomes are an important element in furthering our understanding of GBS disease.
